News | Heart Valve Technology | November 26, 2019 | Dave Fornell, Editor

TriClip Device For Tricuspid Regurgitation Effective at One Year in TRILUMINATE Study

Preliminary results of TRILUMINATE pivotal trial shows good safety and reduction of TR in 87 percent of patients

A key slide from the TRILUMINATE study one-year results showing the improvement in tricuspid regurgitation from basement with treatment using the transcatheter TriClip device.

A key slide from the TRILUMINATE study one-year results showing the improvement in tricuspid regurgitation from basement with treatment using the transcatheter TriClip device.


November 26, 2019 — The preliminary one-year results of the TRILUMINATE Pivotal Study for Abbott's TriClip device, a technical iteration of MitraClip, was found to be safe and effective for edge-to-edge transcatheter repair of tricuspid regurgitation (TR).

The data was shared during a late-breaking session at London Valves by Professor Georg Nickenig, lead investigator of the study and chair of Internal Medicine and Polyclinic II at the University of Bonn, Germany, presented findings. Data show a TR reduction of at least one grade in 87 percent of patients with symptomatic or greater TR and improvements in quality-of-life. 

The study also found low major adverse event rates at 1 year, with no new device-related events after 30 days. There was a significant improvement in NYHA heart failure class I/II (22% to 80%), KCCQ (16.8 points) and 6-minute walk (33.1 meters) persisted at one year. 

Nickenig said at the reduction of TR was associated with significantly decreased right ventricular (RV) dimensions, suggesting positive remodeling, with significant improvement in RV function.

The proportion of subjects with moderate or less TR increased from 4 percent at baseline to 54 percent at 30 days, and 64 percent at one year, indicating a durable TR repair, Nickenig explained. 

Continued improvements in NYHA functional class from 30 days to 1-year.

The TriClip is a version of the MitraClip used for transcatheter mitral valve repair (TMVR) to resolve mitral regurgitation. A post hoc registry analysis of MitraClip use for TR has indicated TR reduction and improved clinical outcomes out to one year.[1,2,3]

 

The Current Standard of Care for Tricuspid Regurgitation 

Tricuspid regurgitation (TR) is a frequent disease with poor prognosis. Treatment for TR is currently limited to the use of diuretics and high-risk surgical procedures. Nickenig said minimally invasive catheter-based procedures (such as TriClip) may reduce TR with low procedural risk.

Investigators in the TRILUMINATE Trial include Georg Nickenig, M.D.; Marcel Weber, M.D.; Phillip Lurz, M.D.; Paul Sorajja, M.D.; Jörg Hausleiter, M.D.; Marta Sitges, M.D.; Paolo Denti, M.D.; Jean-Noël Trochu, M.D., Ph.D.; Michael Nabauer, M.D.; and Rebecca T. Hahn, M.D.

 

Related TriClip and TRILUMINATE  Content:

Abbott Launches Pivotal Trial of TriClip Tricuspid Valve Repair System

Abbott Tricuspid Valve Repair System Reduces Tricuspid Regurgitation at 30 Days

VIDEO: Tricuspid Valve Imaging and Interventions Developing Hand-in-hand — Interview with Rebecca Hahn, M.D.

Advances in Transcatheter Tricuspid Valve Technologies

VIDEO: Tricuspid Device Clinical Trial Overview — Interview with Ori Ben-Yehuda, M.D.

Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System

Minneapolis Heart Institute Foundation Enrolls First Patient in TRILUMINATE Tricuspid Repair Trial

 

References:

1. Nickenig G et al.,Transcatheter Treatment of Severe Tricuspid Regurgitation With the Edge-to-Edge MitraClip Technique. Circulation. 2017;135(19):1802-1814.
2. Mehr M et al.,
1-Year Outcomes After Edge-to-Edge Valve Repair for Symptomatic Tricuspid Regurgitation. JACC Cardiovasc Interv. 2019;12(15):1451-1461.
3. Besler C et al., Predictors of Procedural and Clinical Outcomes in Patients With Symptomatic Tricuspid Regurgitation Undergoing Transcatheter Edge-to-Edge Repair.JACC Cardiovasc Interv. 2018;11(12):1119-1128.

 

Related Content

News | Cardiovascular Clinical Studies

June 24, 2021 — Data captured in American College of Cardiology (ACC) National Cardiovascular Data Registry (NCDR) ...

Home June 24, 2021
Home
News | Cardiovascular Clinical Studies

January 27, 2021 — A New York Institute of Technology research team has secured a five-year $1.8 million grant from the ...

Home January 27, 2021
Home
News | Cardiovascular Clinical Studies

July 22, 2020 — Eating chocolate at least once a week is linked with a reduced risk of heart disease, according to ...

Home July 22, 2020
Home
News | Cardiovascular Clinical Studies

July 1, 2020 — Carag AG announced receiving U.S. Food and Drug Administration (FDA) Investigational Device Exemption ...

Home July 01, 2020
Home
News | Cardiovascular Clinical Studies

January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special ...

Home January 20, 2020
Home
News | Cardiovascular Clinical Studies

Environmental and lifestyle issues were popular this year, with pick up from both European Society of Cardiology (ESC) ...

Home December 23, 2019
Home
News | Cardiovascular Clinical Studies

November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have ...

Home November 26, 2019
Home
News | Cardiovascular Clinical Studies

July 10, 2019 — The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During ...

Home July 10, 2019
Home
News | Cardiovascular Clinical Studies

July 3, 2019 — The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to ...

Home July 03, 2019
Home
News | Cardiovascular Clinical Studies

November 19, 2018 — The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent ...

Home November 19, 2018
Home
Subscribe Now